Pham, F.; Belkaid, S.; Maillet, D.; Confavreux, C.B.; Dalle, S.; Péron, J.
Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab. Biomedicines 2022, 10, 2758.
https://doi.org/10.3390/biomedicines10112758
AMA Style
Pham F, Belkaid S, Maillet D, Confavreux CB, Dalle S, Péron J.
Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab. Biomedicines. 2022; 10(11):2758.
https://doi.org/10.3390/biomedicines10112758
Chicago/Turabian Style
Pham, Félix, Samy Belkaid, Denis Maillet, Cyrille B. Confavreux, Stéphane Dalle, and Julien Péron.
2022. "Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab" Biomedicines 10, no. 11: 2758.
https://doi.org/10.3390/biomedicines10112758
APA Style
Pham, F., Belkaid, S., Maillet, D., Confavreux, C. B., Dalle, S., & Péron, J.
(2022). Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab. Biomedicines, 10(11), 2758.
https://doi.org/10.3390/biomedicines10112758